Who we are
Neuroservice is a private Contract Research Organization providing pharmacological assays based on electrophysiological recordings of acute brain slices, spinal cord slices, human brain slices and cultured neurons. These assays are performed with two complementary techniques: the Multi-Electrode Array (MEA) and the Patch-Clamp.

The mission of Neuroservice is to support the early phases of CNS and PAIN R&D programs in Lead Selection & Optimization as well as in the investigation of Mechanism of Action for experimental compounds. Neuroservice is also able to perform electrophysiological recordings of slices from genetically engineered rodents and to address CNS Safety/Toxicology issues for any given compound, thanks to our cutting-edge electrophysiological screening platform.
Our commitments
Expertise
interactive and expert support
Flexibility
user-friendly interface with clients
Quality
robust & reproducible data
Efficiency
mid-troughtput production capabilities
Ethics
minimized animal use
Innovation
active intern R&D programs
Neuroservice blog
Blog
What is the precise action of your anti-epileptic drug on neuronal networks and on neurotransmission?
Electrophysiology changes the game     Demonstrating that a potential anti-epileptic compound has the expected effect requires different stages of analysis, at the neuronal network but also at the cellular level. Two electrophysiological techniques, the Multi-Electrode Array and the patch-clamp, greatly aid in these analyses in a highlyRead more...
Cognition studies: your lead compound works in vivo but its mechanism of action (MOA) remains unclear?
    Bruno Buisson, founder, general manager & chief scientist at Neuroservice, explains how electrophysiology can illuminate pharmacological compound profile, providing a clearer understanding of mechanism of action, with an in vitro approach for cognition mechanisms on a true neuronal network.     COGNITION STUDIES: INSUFFICIENT INFORMATION ONRead more...
Olesoxime, a first hope for Spinal Muscular Atrophy (SMA) patients
About the author  Thierry Bordet has more than 15 years of experience leading drug discovery efforts from preclinical research to proof-of-concept across biotech and academic settings. At Trophos, Thierry led various drug discovery programs for motor neuron disorders which culminated in the identification of Olesoxime, the first treatmentRead more...
The Evolution of the Contract Research Organization
Jeff is a neuropharmacologist by training with 20 years of experience in the drug discovery divisions of top-tier Pharma organizations.  In the last 4 years he has shifted his efforts to consulting and presently counts both biotechs and CROs as clients.  In part, Jeff works to identify projectRead more...
Neuroservice blog is launched!
By Bruno Buisson, PhD, Founder, General Manager & Chief Scientist at Neuroservice. It is a great pleasure and honor to release the first article of the Neuroservice Blog: a forum for scientists or experts who want to share information about hot topics in neurobiology, electrophysiology, drug discovery, CRO...Read more...
Highlighting of the brain for healthcare enlightenment
By Franck DEBARBIEUX, PhD, Scientific Manager of “Intravital Cellular Imaging Technologies” platform (ICI Tech) at CERIMED, Principal Investigator of IMAPATH team at Institut de Neuroscience Timone (INT). Largescale interdiciplinary interactions between diverse scientific communities have nutured a powerful revolution that is ready to boost the field of NeuroscienceRead more...
Can reverse translational research help discovery of analgesic drugs?
By Alain ESCHALIER, MD, PhD, PharmD, Professor of Pharmacology, Director of the Inserm Unit Neuro-Dol, Faculty of Medicine, University of Auvergne, CHU Clermont-Ferrand; President of the Analgesia Institute. Regarding the poor innovation in the pharmacological management of pain, we show in this article, through two research stories, thatRead more...
Neuroservice channel
Videos
Neuroservice news
News
Home